HOME Research Insight Molecular Diagnotics key strategy is to expand its market through acquisitions, connecting financially with companies having common values and goals



Molecular Diagnotics key strategy is to expand its market through acquisitions, connecting financially with companies having common values and goals


The key players in the molecular diagnostics market are Roche Diagnostics (Switzerland), Gen-Probe (Hologic) (U.S.), QIAGEN (Netherlands), Becton, Dickinson & Company (U.S.), Siemens Healthcare (Germany), bioMérieux (France), Abbott Laboratories (U.S.), Novartis AG (Switzerland), Cepheid (U.S.), and Beckman Coulter (U.S.). The molecular diagnostics market is highly fragmented, with Roche Diagnostics and Novartis AG leading most of the segments. However, each segment is dominated by different players owing to their core competencies.

Roche Diagnostics has emerged as the market leader in the global molecular diagnostics market, and is likely to maintain its leadership position in the coming years. The company manufactures and markets diagnostic products. Its prime focus is on expanding and entering into segments for new markers and technology for molecular diagnostic products. The key strategy is to expand its market through acquisitions, connecting financially with companies having common values and goals. To gain the maximum market share, the company has been aggressively adopting the strategy of agreements, collaborations, and partnerships with third party vendors. So far, the company has partnered with IQuum, Inc. (U.S.), mtm laboratories AG (Germany), PVT Probenverteiltechnik GmbH (Germany), and PVT Lab Systems LLC (U.S.).

Novartis AG occupies the second position in the molecular diagnostics market. The company is involved in the development of healthcare products. It has a broad expertise in pharmaceuticals, vaccines, and diagnostics. The company strategically focuses on product launches and innovations as a key strategy for its growth. To obtain the maximum market share, the company has also been extensively adopting the strategy of agreements, collaborations, and partnerships with third party vendors.

The in depth research in the molecular diagnostics market has discovered that agreements, partnerships, and collaborations are the key strategies adopted by major players to enhance their existing portfolios. This strategy has widened the companies’ offerings across geographies and enhanced their existing portfolios of products and services. Besides generating revenues from the developed markets, the companies are also making the most of the opportunities offered to them by the emerging markets.

The major players that adopted this strategy were Roche Diagnostics (Switzerland), Novartis AG (Switzerland), Hologic Gen-Probe (U.S.), and QIAGEN (Netherlands). In April 2014, Roche acquired the U.S.-based IQuum, Inc., a point-of-care molecular diagnostics company. This enables Roche to access IQuum’s technology such as Laboratory-in-a-tube (Liat) System that helps in performing rapid, reliable, and accurate molecular diagnostic tests in point-of-care settings.

Related Reports:

Molecular Diagnostics Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports